"As a global expert in rare diseases and with invaluable experience steering a company from early stage through to a publicly listed company nearing commercialization, we welcome Mr. Schikan to BIO's board. His expertise in these areas, together with his pioneering experience in the Duchenne Muscular Dystrophy (DMD) space, will prove essential as we continue to work with regulators globally to expedite treatment options for major unmet medical needs," said Cartier Esham, BIO's Executive Vice President of Emerging Companies.
In addition to his role as Chief Executive Officer of Prosensa, Mr. Schikan also serves as Non-executive Director of Swedish Orphan Biovitrum A.B., Executive Board Member of the Dutch Top Institute Pharma, and Member of the Core Team of the Dutch Top Sector Life Sciences & Health. He is also past Chairman of Nefarma, the
"I am delighted to be joining the BIO Emerging Companies Section Governing Board and work alongside other industry leaders to continue to advance the biotechnology industry", said Mr. Schikan.
"BIO's work is crucial to helping emerging companies thrive in this challenging space. The work BIO has accomplished in recent years with significant contributions to the JOBS Act and FDASIA have enabled innovators like Prosensa to more easily access the capital markets and work more collaboratively with regulators. I look forward to drawing from my experience to continue to promote innovation for the benefit of patients and industry," he said.
Notes to editors
About Hans GCP Schikan, Chief Executive Officer
Hans Schikan, 55, has served as Chief Executive Officer of
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), Myotonic dystrophy and Huntington's disease.
Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in
CONTACT: Prosensa Holding N.V.
Celia Economides, Senior Director IR & Corporate Communications Email: firstname.lastname@example.org
Source: Prosensa Holding N.V.